Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19
A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19
Sponsor: John Hopkins Aramco Healthcare
This PHASE2 trial investigates Convalescent Plasma for COVID 19 and is currently completed. John Hopkins Aramco Healthcare leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Mar 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jun 2020 — Sep 2020 [monthly]
Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE2
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- John Hopkins Aramco Healthcare
- King Abdulaziz Medical City
- King Fahad Medical City
- King Fahad Military Medical Complex
- King Fahad Specialist Hospital Dammam
- King Fahad University Hospital
- King Faisal Specialist Hospital & Research Center
- King Khaled University Hospital
- King Saud University
- Qatif Central Hospital
- Taibah University
For direct contact, visit the study record on ClinicalTrials.gov .